Oculis Holding AG (NASDAQ:OCS) Given Consensus Recommendation of “Buy” by Analysts

Shares of Oculis Holding AG (NASDAQ:OCS) have been assigned an average rating of “Buy” from the six research firms that are presently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $30.17.

OCS has been the subject of a number of recent analyst reports. HC Wainwright raised their target price on Oculis from $28.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, June 11th. Robert W. Baird raised their target price on Oculis from $35.00 to $37.00 and gave the company an “outperform” rating in a report on Tuesday, June 11th. Chardan Capital reissued a “buy” rating and issued a $30.00 target price on shares of Oculis in a report on Tuesday, June 11th. Finally, Bank of America reduced their target price on Oculis from $21.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, June 11th.

Oculis Price Performance

Shares of NASDAQ OCS opened at $11.69 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.71 and a quick ratio of 4.71. The stock has a fifty day moving average price of $11.76 and a 200 day moving average price of $11.93. Oculis has a 1-year low of $9.05 and a 1-year high of $14.50. The company has a market cap of $473.45 million, a PE ratio of -6.57 and a beta of 0.28.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.03). Oculis had a negative return on equity of 52.72% and a negative net margin of 6,712.02%. The company had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.28 million. Sell-side analysts forecast that Oculis will post -1.92 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Searle & CO. purchased a new stake in Oculis during the 4th quarter worth about $112,000. Compagnie Lombard Odier SCmA increased its position in Oculis by 47.3% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock worth $1,053,000 after purchasing an additional 30,750 shares in the last quarter. Finally, abrdn plc purchased a new stake in Oculis during the 4th quarter worth about $15,980,000. Hedge funds and other institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.